Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558262 | 1.00 | KDM4E (0.54) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL12635860 | 0.88 | KDM4E (0.56) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL30288086 | 0.87 | GPR119 (0.52) | KDM4EPKMGPR119ACHE | |
| SCHEMBL8825578 | 0.87 | ACHE (0.64) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL29890980 | 0.87 | ACHE (0.64) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL6953531 | 0.86 | ACHE (0.55) | KDM4EPKMGPR119ACHE | |
| SCHEMBL5475624 | 0.84 | ACHE (0.53) | KDM4EPKMGPR119ACHE | |
| SCHEMBL31596884 | 0.83 | GPR119 (0.53) | KDM4EPKMGPR119ACHE | |
| SCHEMBL23884184 | 0.82 | ACHE (0.51) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL22849388 | 0.81 | GPR119 (0.57) | KDM4EPKMGPR119BRD4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025852-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025852-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | KDM4E 2981/4885PKM 3633/4885GPR119 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.